Cargando…
Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections
Several studies have demonstrated that piperacillin/tazobactam produces a false-positive result for the galactomannan antigen test. However, the most recent literature has demonstrated that this interaction is no longer a concern. There is little information regarding the drug–laboratory interaction...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428187/ https://www.ncbi.nlm.nih.gov/pubmed/24833197 http://dx.doi.org/10.1016/j.bjid.2014.03.009 |
_version_ | 1784779056512761856 |
---|---|
author | Otting, Kristin A. Stover, Kayla R. Cleary, John D. |
author_facet | Otting, Kristin A. Stover, Kayla R. Cleary, John D. |
author_sort | Otting, Kristin A. |
collection | PubMed |
description | Several studies have demonstrated that piperacillin/tazobactam produces a false-positive result for the galactomannan antigen test. However, the most recent literature has demonstrated that this interaction is no longer a concern. There is little information regarding the drug–laboratory interaction with the generics of piperacillin/tazobactam or other broad-spectrum beta-lactams, such as ceftaroline, doripenem, imipenem/cilastatin, and meropenem. The purpose of this study was to determine if a drug–laboratory interaction exists with these antibiotics. Tests showed that one lot of imipenem/cilastatin by Hospira Healthcare India Private Limited produced a false-positive result for the galactomannan antigen test. All other medications tested, including piperacillin/tazobactam from seven manufacturers and imipenem/cilastatin by Hospira Inc., did not produce positive results. Since the reason for this drug–laboratory interaction with imipenem/cilastatin is unknown, more studies are needed to further investigate this interaction. Providers also should be educated of these findings: no drug–laboratory interaction with piperacillin/tazobactam and a possible drug–laboratory interaction with imipenem/cilastatin (Hospira Healthcare India Private Limited). |
format | Online Article Text |
id | pubmed-9428187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94281872022-09-01 Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections Otting, Kristin A. Stover, Kayla R. Cleary, John D. Braz J Infect Dis Brief Communication Several studies have demonstrated that piperacillin/tazobactam produces a false-positive result for the galactomannan antigen test. However, the most recent literature has demonstrated that this interaction is no longer a concern. There is little information regarding the drug–laboratory interaction with the generics of piperacillin/tazobactam or other broad-spectrum beta-lactams, such as ceftaroline, doripenem, imipenem/cilastatin, and meropenem. The purpose of this study was to determine if a drug–laboratory interaction exists with these antibiotics. Tests showed that one lot of imipenem/cilastatin by Hospira Healthcare India Private Limited produced a false-positive result for the galactomannan antigen test. All other medications tested, including piperacillin/tazobactam from seven manufacturers and imipenem/cilastatin by Hospira Inc., did not produce positive results. Since the reason for this drug–laboratory interaction with imipenem/cilastatin is unknown, more studies are needed to further investigate this interaction. Providers also should be educated of these findings: no drug–laboratory interaction with piperacillin/tazobactam and a possible drug–laboratory interaction with imipenem/cilastatin (Hospira Healthcare India Private Limited). Elsevier 2014-05-13 /pmc/articles/PMC9428187/ /pubmed/24833197 http://dx.doi.org/10.1016/j.bjid.2014.03.009 Text en © 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Communication Otting, Kristin A. Stover, Kayla R. Cleary, John D. Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
title | Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
title_full | Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
title_fullStr | Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
title_full_unstemmed | Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
title_short | Drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
title_sort | drug–laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428187/ https://www.ncbi.nlm.nih.gov/pubmed/24833197 http://dx.doi.org/10.1016/j.bjid.2014.03.009 |
work_keys_str_mv | AT ottingkristina druglaboratoryinteractionbetweenbetalactamantibioticsandthegalactomannanantigentestusedtodetectmouldinfections AT stoverkaylar druglaboratoryinteractionbetweenbetalactamantibioticsandthegalactomannanantigentestusedtodetectmouldinfections AT clearyjohnd druglaboratoryinteractionbetweenbetalactamantibioticsandthegalactomannanantigentestusedtodetectmouldinfections |